Overview
This observational study is a large-scale, prospective, and multi-institutional observational study.
Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.
Description
Data will be collected based on patient's medical records from daily visit. Enrolled subjects will take a Patient Reported Outcome (PRO) survey including Quality of life evaluation (GERD-HRQL) and self-awareness symptom (RDQ).
The survey will be done twice (before and after the administration of Fexuclue tablet) electronically through an application (e-PRO).
Eligibility
Inclusion Criteria:
- Adult aged 19 years to 75 years (on registration date)
- Patient scheduled to administer Fexuclue tablet based on the medical judgment of investigator.
- Patient who has not taken a treatment for gastroesophageal reflux disease within two weeks from baseline visit.
- Patient who agreed to participate in this observation study and signed Informed Consent Form
Exclusion Criteria:
- A person who falls under the prohibition of administration according to the permission
for Fexuclue Tablet
- Patients with hypersensitivity to the components of Fexuclue tablet or Fexuclue tablet and a history thereof
- Patients undergoing Atazanavir, Nelfinavir or Lilpivirin-containing preparations
- Pregnant and lactating women
- Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabortion
- A person who has taken a treatment for gastroesophageal reflux disease within two
weeks from baseline visit.
- In addition to the above, a person who has determined that the researcher (the doctor in charge) is not suitable for participation in this observation study